-
BioGeneration Ventures co-leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programma
December 14, 2017BGV co-leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programme Lead drug icosabutate,...
0 -
BioGeneration Ventures Fund III reaches EUR 82 million in final close
October 31, 2017BioGeneration Ventures Fund III reaches EUR 82 million in final close Investments from Bristol-Myers Squibb and Johnson & Johnson...
-
BioGeneration Ventures Fund III Secures EUR 66m, exceed EUR 50m target
June 27, 2017Naarden, The Netherlands, 27 June 2017 – BioGeneration Ventures (BGV), the early stage Life Sciences Venture Capital firm with...
-
BioGeneration Ventures portfolio company Cristal Therapeutics raises €12.8 million in a new financing round
January 19, 2017BioGeneration Ventures portfolio company Cristal Therapeutics raises €12.8 million ($13.7m) in a new financing round. Read full press release...
-
Van Start-up naar miljardenbedrijf
November 3, 2016Lees hier het complete interview met Edward van Wezel (BioGeneration) en Allard Kaptein en Tjeerd Barf (Acerta) uit het Financieel...